Roots Analysis

AUGUST 28, 2022

The up-and-coming field of spatial genomics in biology promises to bridge the gap between high plex, high throughput, and high resolution. 70+ spatial Genomics solutions are developed by industry and non-industry players. 70+ spatial Genomics solutions are developed by industry and non-industry players. Concluding Remarks.

Genome 52

Genome Genomics RNA Genome Project 52

BioTech 365

SEPTEMBER 15, 2020

–(BUSINESS WIRE)–ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property (IP) co-owned by Dr. Emmanuelle Charpentier, today announced it has signed an agreement with Applied StemCell, Inc., DUBLIN & MILPITAS, Calif.–(BUSINESS

Genome 40

Genome Genomics Gene Editing Reagent 40

The Pharma Data

JANUARY 31, 2021

It is dubbed the Sequoia Capital China Intelligent Healthcare Genomics Incubator, Powered by Illumina. The focus will be on building life science startups specializing in genomics. Participating startups must locate at the genomics incubator facility in Shanghai, China during the six-month cycle.

Life Science 52

Life Science Genome Genomics Reagent 52

The Pharma Data

OCTOBER 27, 2020

.” The single-reaction panel targets five regions of the viral genome and provides excellent accuracy and sensitivity. “Most real time qPCR-based assays target only two or three targets on the viral genome.” “Most real time qPCR-based assays target only two or three targets on the viral genome.”

Genetic Analysis 52

Genetic Analysis Genome Genomics Reagent 52

pharmaphorum

FEBRUARY 3, 2021

This can be partly attributed to the reagents and delivery modalities that were available at the time of the trial start in 2016, leading to low editing efficiency at the target loci. However, the number of CAR-T cells with all four genes correctly targeted was low.

Gene Editing 98

Gene Editing Gene DNA Engineer 98

Roots Analysis

FEBRUARY 21, 2022

Since the introduction of a gene sequencing method by Frederick Sanger in 1977, the field of genomic data collection and analysis has evolved significantly. Moreover, the manual protocols require extensive manipulation, costly reagents and long duration of skilled genomic library production. Nanoparticles Contract Manufacturing.

Marketing 52

Marketing Gene Sequencing DNA Genome 52

XTalks

AUGUST 18, 2020

Instead of RNA extraction, the Yale test involves use of a reagent that when mixed with a saliva sample and heated for a short period of time, releases the viral genome for subsequent detection with PCR. This is significant because shortages of RNA extraction kits have been a recurrent issue since the beginning of the pandemic.

FDA Approval 90

FDA Approval Reagent RNA Genome 90

The Pharma Data

MARCH 20, 2021

The Challenge: The demands of many labs simultaneously beginning COVID-19 screening programs are leading to a scarcity of resources like pipette tips and reagents. delays where reagents are in. professor in Functional Cancer Genomics and Applied. significant miniaturization and reduction in reagent. The MANTIS.

Reagent 52

Reagent RNA Bioinformatics Medicine 52

Pharmaceutical Technology

FEBRUARY 15, 2023

Outlook The era of mRNA-based genomic medicines is on the horizon. PNI’s GenVoy Delivery Platform comprises off-the-shelf RUO reagents such as GenVoy-ILM and a library of proprietary lipids available as custom formulations. The technology underpinning the COVID-19 vaccines are the tip of the iceberg.

Bioassay 130

Bioassay RNA Development Drugs 130

XTalks

JANUARY 21, 2025

The Onclarity HPV reagent pack extraction combo. Illumina says TruSight Oncology Comprehensive is the first US FDA-approved, distributable comprehensive genomic profiling IVD kit with pan-cancer companion diagnostic claims. Photo courtesy of BD. The diagnostic tests for more than 500 genes to profile tumors.

FDA Approval 105

FDA Approval Manufacturing Development RNA 105

Roots Analysis

FEBRUARY 23, 2022

Over the past few years, several companies have started offering a diverse range of genome sequencing products and services using various second and third generation sequencing technologies. Next Generation Sequencing (NGS) Library Preparation Kits. Strong Intellectual Property Portfolio.

Genetics 52

Genetics DNA RNA Reagent 52

The Pharma Data

JANUARY 24, 2021

Dr. Bond has extensive experience in the discovery and development of adoptive cell therapies, monoclonal antibodies, and cellular engineering and genome editing. As part of his work with Juno and Kite, Dr. Bond led R&D collaborations with genome editing companies including Editas Medicine and Sangamo Therapeutics.

Engineer 52

Engineer Gene Editing Genome Genomics 52

The Pharma Data

DECEMBER 2, 2020

ERS Genomics – Ireland’s ERS Genomics Limited, and Germany’s Vivlion GmbH, announced a non-exclusive license agreement granting Vivlion access to ERS Genomics’ CRISPR/Cas9 patent portfolio, to enhance Vivlion’s gene editing reagents and screening services. Financial details of the agreement were not disclosed.

Drugs 52

Drugs Gene Editing Genome Genomics 52

Pharmaceutical Technology

FEBRUARY 3, 2023

The field of genomic medicine has reached a true turning point. For each production process, you have to generate the plasmids in huge quantities with GMP quality and then do a transient transfection, meaning you mix them with a transfection reagent and add that to the cells in a very controlled way,” explains Faust.

Genome 244

Genome Genomics Medicine Gene Therapy 244

The Pharma Data

OCTOBER 14, 2020

They offer access to an intact genome which allows whole genome sequencing without a background. 2) Prenatal Diagnostics : circulating throphoblasts in maternal blood can provide a comprehensive, non-invasive picture of a fetus as well as access to an intact genome. Whole cells are precious biomarkers.

Clinical Trials 40

Clinical Trials Clinical Trials Trials Genome 40

Advarra

NOVEMBER 29, 2022

Bottlenecks in the manufacturing process, supply chain issues such as accessibility of good manufacturing practice (GMP)-grade reagents, and shortages of qualified scientists and engineers have caused many therapies to fail at critical stages of the clinical development pipeline. But review issues are not the only problems.

Gene Therapy 52

Gene Therapy Gene Production Clinical Trials 52

XTalks

OCTOBER 19, 2023

This could involve tweaking experimental conditions, changing reagents or redesigning the assay. Additionally, advances in technologies in fields like genomics, proteomics and cell biology necessitate specialized assays.

Scientist 59

Scientist Development Research Compliance 59

The Pharma Data

OCTOBER 14, 2020

ERS Genomics – Ireland’s ERS Genomics signed an agreement with FASMAC Co., Under the terms of the non-exclusive agreement FASMAC acquires the right to use CRISPR/Cas9 technology and commercialize tools and reagents associated with it. The patent is valid through 2038. Ltd of Japan.

Clinical Trials 52

Clinical Trials Clinical Trials Manufacturing In-Vivo 52

The Pharma Data

JANUARY 20, 2021

Laboratory Implementation Laboratory reagents for performing the test commercially have been designed and are currently being validated in preparation for regulatory submission to CMS/CLIA with a view to targeting sales in the USA initially. This is also expected to provide greater flexibility for potential distribution partners.

Genetics 40

Genetics Reagent Biobanking Production 40

XTalks

JANUARY 6, 2025

Additionally, CRISPR genome-wide screening holds great potential for identifying key disease-associated genes and uncovering novel therapeutic targets. NGS technology has revolutionized genetic analysis, enabling laboratories to rapidly sequence whole genomes, deeply sequence target regions and identify novel pathogens.

Gene Therapy 111

Gene Therapy RNA Gene Editing Gene 111

Roots Analysis

JANUARY 27, 2025

Recent protein expression market trends showcase a growing emphasis on cell free protein expression systems, advanced bioinformatics, and the rise of the protein expression market for kits and reagents. Patients are increasingly seeking personalized therapies, stimulating the demand for customizable and scalable protein expression platforms.

Protein 40

Protein Reagent Marketing Gene 40